v3.24.3

Condensed Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,378,304	$ 8,839,912
Prepaid expenses and other assets	73,138	109,243
Total current assets	6,451,442	8,949,155
Total assets	6,451,442	8,949,155
Current liabilities:
Accounts payable	1,706	33,731
Accrued expenses and other liabilities	42,853	631,433
Total current liabilities	44,559	665,164
Deferred revenue	3,000,000	3,000,000
Total liabilities	3,044,559	3,665,164
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 172,323,545 and 172,023,545 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	17,232	17,202
Additional paid-in capital	54,087,065	54,046,845
Accumulated deficit	(50,697,414)	(48,780,056)
Total stockholders’ equity	3,406,883	5,283,991
Total liabilities and stockholders’ equity	6,451,442	8,949,155
Series A Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Undesignated Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Inhibitor Therapeutics, Inc. 10-Q